US-based Ritter Pharmaceuticals has reported positive additional results from a Phase IIb/III trial of its product candidate RP-G28 in patients suffering from lactose intolerance (LI).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Lactose is a sugar present in milk and related products, while RP-G28 is non-digestible oligosaccharide currently being developed to regulate gastrointestinal (GI) tract bacteria to metabolise lactose for improved tolerance.
According to the results, RP-G28 showed a clear drug effect with a significant and clinically meaningful reduction in LI symptoms as assessed by different global and real world outcome measures.
Ritter Pharmaceuticals president and co-founder Andrew Ritter said: “As we continue to evaluate the results of this trial, we are increasingly excited by the strength of the data supporting RP-G28’s potentially significant and durable real-world treatment effect for patients suffering from lactose intolerance.”
During the multi-centre, randomised, doubled-blind, placebo-controlled, parallel-group Phase IIb/III trial, the efficacy, safety and tolerability of RP-G28 were evaluated in 377 subjects.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe trial comprised a 30-day treatment phase and a post-treatment real-world observation phase of additional 30 days, during which subjects consumed lactose containing food products.
With a composite primary endpoint of abdominal pain, cramping, bloating and gas movement, the trial monitored post-treatment LI symptoms using a Likert scale.
After the re-introduction of dairy and milk products into subjects’ diets, 83% reported LI symptoms relief and 82% experienced no or mild symptom severity.
Furthermore, RP-G28 was found to be safe without any serious adverse events related to the treatment.
Ritter intends to initiate a Phase III programme for RP-G28 in the first half of next year and has already started manufacturing efforts.
Image: Lactose is found in milk and dairy products. Photo: courtesy of World's Direction/flickr.
